188 related articles for article (PubMed ID: 33382729)
1. Successful direct-acting antiviral therapy improves circulating mucosal-associated invariant T cells in patients with chronic HCV infection.
Khlaiphuengsin A; Chuaypen N; Sodsai P; Reantragoon R; Han WM; Avihingsanon A; Tangkijvanich P
PLoS One; 2020; 15(12):e0244112. PubMed ID: 33382729
[TBL] [Abstract][Full Text] [Related]
2. Mucosal-associated invariant T-cell frequency and function in blood and liver of HCV mono- and HCV/HIV co-infected patients with advanced fibrosis.
Beudeker BJB; van Oord GW; Arends JE; Schulze Zur Wiesch J; van der Heide MS; de Knegt RJ; Verbon A; Boonstra A; Claassen MAA
Liver Int; 2018 Mar; 38(3):458-468. PubMed ID: 28792648
[TBL] [Abstract][Full Text] [Related]
3. Intra-Hepatic Depletion of Mucosal-Associated Invariant T Cells in Hepatitis C Virus-Induced Liver Inflammation.
Bolte FJ; O'Keefe AC; Webb LM; Serti E; Rivera E; Liang TJ; Ghany M; Rehermann B
Gastroenterology; 2017 Nov; 153(5):1392-1403.e2. PubMed ID: 28780074
[TBL] [Abstract][Full Text] [Related]
4. Frequencies of Circulating MAIT Cells Are Diminished in Chronic HCV, HIV and HCV/HIV Co-Infection and Do Not Recover during Therapy.
Spaan M; Hullegie SJ; Beudeker BJ; Kreefft K; van Oord GW; Groothuismink ZM; van Tilborg M; Rijnders B; de Knegt RJ; Claassen MA; Boonstra A
PLoS One; 2016; 11(7):e0159243. PubMed ID: 27416100
[TBL] [Abstract][Full Text] [Related]
5. Improvement of Gut Diversity and Composition After Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients With or Without Human Immunodeficiency Virus Coinfection.
Chuaypen N; Jinato T; Avihingsanon A; Chirapongsathorn S; Cheevadhanarak S; Nookaew I; Tanaka Y; Tangkijvanich P
J Infect Dis; 2021 Oct; 224(8):1410-1421. PubMed ID: 33598686
[TBL] [Abstract][Full Text] [Related]
6. Elbasvir-grazoprevir: A new direct-acting antiviral combination for hepatitis C.
Karaoui LR; Mansour H; Chahine EB
Am J Health Syst Pharm; 2017 Oct; 74(19):1533-1540. PubMed ID: 28947524
[TBL] [Abstract][Full Text] [Related]
7. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Moll A; Jäger H; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
HIV Med; 2018 Apr; 19(4):299-307. PubMed ID: 29368456
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.
Gane EJ; Pianko S; Roberts SK; Thompson AJ; Zeuzem S; Zuckerman E; Ben-Ari Z; Foster GR; Agarwal K; Laursen AL; Gerstoft J; Gao W; Huang HC; Fitzgerald B; Fernsler D; Li JJ; Grandhi A; Liu H; Su FH; Wan S; Zeng Z; Chen HL; Dutko FJ; Nguyen BT; Wahl J; Robertson MN; Barr E; Yeh WW; Plank RM; Butterton JR; Esteban R
Lancet Gastroenterol Hepatol; 2017 Nov; 2(11):805-813. PubMed ID: 28802816
[TBL] [Abstract][Full Text] [Related]
9. Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4.
El Kassas M; Elbaz T; Abd El Latif Y; Esmat G
Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1413-1421. PubMed ID: 27603877
[TBL] [Abstract][Full Text] [Related]
10. Nonreversible MAIT cell-dysfunction in chronic hepatitis C virus infection despite successful interferon-free therapy.
Hengst J; Strunz B; Deterding K; Ljunggren HG; Leeansyah E; Manns MP; Cornberg M; Sandberg JK; Wedemeyer H; Björkström NK
Eur J Immunol; 2016 Sep; 46(9):2204-10. PubMed ID: 27296288
[TBL] [Abstract][Full Text] [Related]
11. An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions.
Huang CF; Hung CH; Cheng PN; Bair MJ; Huang YH; Kao JH; Hsu SJ; Lee PL; Chen JJ; Chien RN; Peng CY; Lin CY; Hsieh TY; Cheng CH; Dai CY; Huang JF; Chuang WL; Yu ML
J Infect Dis; 2019 Jul; 220(4):557-566. PubMed ID: 30957170
[TBL] [Abstract][Full Text] [Related]
12. Liver stiffness regression after successful Hepatitis C treatment is independent of HIV coinfection.
Malin JJ; Boesecke C; Schwarze-Zander C; Wasmuth JC; Schlabe S; Trebicka J; Spengler U; Llibre JM; Jou T; Vasylyev M; Clotet B; Rockstroh JK
HIV Med; 2019 Mar; 20(3):230-236. PubMed ID: 30687989
[TBL] [Abstract][Full Text] [Related]
13. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
[TBL] [Abstract][Full Text] [Related]
14. Immunological recovery in T-cell activation after sustained virologic response among HIV positive and HIV negative chronic Hepatitis C patients.
Emmanuel B; El-Kamary SS; Magder LS; Stafford KA; Charurat ME; Poonia B; Chairez C; McLaughlin M; Hadigan C; Masur H; Kottilil S
Hepatol Int; 2019 May; 13(3):270-276. PubMed ID: 30835046
[TBL] [Abstract][Full Text] [Related]
15. Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
Tada T; Kumada T; Toyoda H; Mizuno K; Sone Y; Kataoka S; Hashinokuchi S
J Gastroenterol Hepatol; 2017 Dec; 32(12):1982-1988. PubMed ID: 28299813
[TBL] [Abstract][Full Text] [Related]
16. MAIT be different-persisting dysfunction after DAA-mediated clearance of chronic hepatitis C virus infection.
Hofmann M; Thimme R
Eur J Immunol; 2016 Sep; 46(9):2099-102. PubMed ID: 27479232
[TBL] [Abstract][Full Text] [Related]
17. Treatment of chronic HCV genotype 1 coinfection.
Boesecke C; Rockstroh JK
Curr HIV/AIDS Rep; 2015 Sep; 12(3):326-35. PubMed ID: 26228050
[TBL] [Abstract][Full Text] [Related]
18. US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection.
Boyd SD; Tracy L; Komatsu TE; Harrington PR; Viswanathan P; Murray J; Sherwat A
Clin Drug Investig; 2017 Apr; 37(4):317-326. PubMed ID: 28102520
[TBL] [Abstract][Full Text] [Related]
19. Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells.
Dias J; Hengst J; Parrot T; Leeansyah E; Lunemann S; Malone DFG; Hardtke S; Strauss O; Zimmer CL; Berglin L; Schirdewahn T; Ciesek S; Marquardt N; von Hahn T; Manns MP; Cornberg M; Ljunggren HG; Wedemeyer H; Sandberg JK; Björkström NK
J Hepatol; 2019 Aug; 71(2):301-312. PubMed ID: 31100314
[TBL] [Abstract][Full Text] [Related]
20. Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting.
Gayam V; Hossain MR; Khalid M; Chakaraborty S; Mukhtar O; Dahal S; Mandal AK; Gill A; Garlapati P; Ramakrishnaiah S; Mowyad K; Sherigar J; Mansour M; Mohanty S
Gut Liver; 2018 Nov; 12(6):694-703. PubMed ID: 29938459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
